Engflag

Romicon-A

Quick links to important sections

Romicon-A

Romicon-A_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Romicon-A

Property Description
Active ingredients Dextromethorphan HBr, Potassium Cresolsulfonate, Lysozyme Cl
Form Oral Capsule (Fixed-Dose Combination)
Pharmacological class Antitussive and Expectorant
Common use Temporary relief of acute cough
Origin Partially Synthetic and Enzyme Derivative

What Type of Medicine is Romicon-A?

Romicon-A is defined as a specialized fixed-dose combination product (FDC), delivered as an oral capsule, that integrates three distinct active ingredients to target acute cough and associated respiratory irritation. This preparation is classified under the combined pharmacological group of Antitussives and Expectorants, reflecting the established dual functional purpose of its components. Dextromethorphan Hydrobromide is a synthetic component that is clinically recognized for its non-opioid central antitussive activity. Dextromethorphan is a cough suppressant that acts centrally. This means the medicine is formulated to help ease the involuntary reflex by acting on the brain's cough center.

Composition and General Therapeutic Purpose

The unique three-part composition of Romicon-A includes Dextromethorphan Hydrobromide, Potassium Cresolsulfonate, and Lysozyme Chloride. The inclusion of Lysozyme Chloride, an enzyme derivative, provides a key differentiating factor, offering supplementary anti-inflammatory support and mild antibacterial effects, distinguishing the preparation from standard two-component cough/cold FDCs. The general therapeutic purpose of this formulation is the temporary relief of acute cough associated with minor throat and bronchial irritation, such as that experienced during a common cold. Potassium Cresolsulfonate functions as an expectorant, which aids in thinning and loosening respiratory mucus. This confirms the medicine supports the body's natural clearing process by making phlegm easier to expel, offering comprehensive symptomatic management for patients experiencing both a constant urge to cough and thick phlegm.

Regulatory References

  1. Potassium Cresolsulfonate (DailyMed)

What side effects are possible with Romicon-A?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse effects and safety constraints for the components of Romicon-A, based strictly on government regulatory documents (e.g., FDA, EMA, national regulatory bodies). This summary is descriptive and contains no dosing, usage instructions, or therapeutic benefits.

Official Adverse Reactions and System-Organ Classes

The adverse effects are formally categorized based on the affected System-Organ Class (SOC) as listed in the regulatory profiles of the active ingredients, primarily Dextromethorphan HBr.

System-Organ Class (SOC) Officially Listed Adverse Reactions
Nervous System Disorders Drowsiness, dizziness, mental confusion, excitation
Gastrointestinal Disorders Nausea, vomiting, diarrhea, stomach pain
Skin Disorders Rash, itching, allergic reactions (e.g., urticaria)

Frequency and Severity

The most frequently documented adverse effects are generally classified as Common, including drowsiness, dizziness, and mild gastrointestinal discomfort. Regulatory documents also note Rare but serious adverse reactions, which include seizures/convulsions and respiratory depression (shallow breathing).

Safety Constraints and Special Populations

Official labeling defines specific conditions under which the medicine should not be used and provides safety notes for certain groups:

  • Contraindication: Use is strictly forbidden for individuals concurrently taking a Monoamine Oxidase Inhibitor (MAOI) or within 14 days of discontinuing an MAOI, due to the documented risk of life-threatening Serotonin Syndrome.
  • Hypersensitivity: The medicine is contraindicated in individuals with known sensitivity to any of its components.
  • Pediatric Use: The safety and effectiveness of the components are not established for use in children under the age of 4 years.
  • Maternal Health: It is officially stated that it is not known if the active ingredient can harm an unborn baby or if it passes into breast milk.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Romicon-A (Dextromethorphan) can lead to serious, dose-related systemic effects affecting the central nervous system and cardiovascular system. It is critical to recognize the signs of excessive ingestion and seek immediate medical attention.

Documented Overdose Presentations

Overdose typically manifests as a progression of symptoms from agitation, confusion, hallucinations, and muscular rigidity to more severe events like seizures and coma. Physiological disturbances often include tachycardia (rapid heart rate), hypertension (high blood pressure), and respiratory depression (slow or shallow breathing). Additional signs may include extreme sweating (diaphoresis) and hyperthermia (severely high body temperature).

When to Seek Urgent Medical Attention

Immediate medical help is required if any symptoms of severe intoxication are present, including altered mental status, convulsions or seizures, hypertensive crisis, or profound hyperthermia. The risk of severe toxicity is particularly heightened when Romicon-A is co-administered with Monoamine Oxidase Inhibitors (MAOIs). Management in a healthcare setting is primarily supportive, focusing on maintaining the airway and stabilizing the patient’s vital signs, which may involve methods such as ventilator support or specific sedatives (like benzodiazepines).

Emergency Actions

If an overdose is suspected, call emergency services immediately. Initial management may involve supportive care, and gastrointestinal decontamination using activated charcoal may be considered if performed promptly.

Therapeutic Uses of Romicon-A

What Romicon-A Treats: Main Uses and Benefits

Romicon-A is a specialized combination used for symptomatic relief in conditions marked by acute respiratory distress. It is commonly applied across domains involving heightened patient discomfort and symptoms that interfere with daily functioning due to temporary illness. The antitussive component is used to temporarily relieve cough caused by common conditions like the cold or flu.

The medication is generally relevant in clinical settings marked by a dry, hacking, or persistent cough, often linked to the common cold or flu, and is also used for situations involving thick respiratory mucus or chest heaviness. It addresses symptom clusters that stem from inflammatory or irritative states in the throat and bronchial lining.

Easing Symptom Burden

This medication is used for managing symptom clusters that may become intense or disruptive, offering supportive symptomatic assistance in conditions characterized by periods of heightened symptoms. The core benefit is providing support that helps ease the overall symptom burden of the persistent reflex, assisting with maintaining functional stability, and contributing to easing the overall symptom load by supporting the management of thick mucus. This application may help patients cope more steadily with symptom fluctuations associated with a productive cough.

Therapeutic Scope: Management of Cough and Congestion

Regulatory References

  1. NIH MedlinePlus overview of Dextromethorphan

Eligibility and Restrictions for Use

Official Eligibility Rules for Romicon-A

The eligibility profile for Romicon-A is defined by specific limitations and prohibitions documented in official governmental regulatory labeling. Use is permitted only for Adults and Children 12 years of age and over under standard conditions.

Regulatory Status Applicable Population or Condition
Contraindicated Children under 12 years of age for this capsule formulation.
Patients taking or who have taken a Monoamine Oxidase Inhibitor (MAOI) within the preceding 14 days.
Individuals with documented hypersensitivity to any component of the product.
Not Recommended/Caution Patients with a chronic or persistent cough (e.g., associated with asthma or smoking), unless medically directed.
Individuals with moderate to severe hepatic impairment (liver dysfunction).
Pregnant or breastfeeding individuals, who must consult a health professional prior to use.

This structure reflects the strict regulatory classification, which defines absolute prohibitions based on severe drug interaction risks (MAOIs) and mandated age minimums. Other restricted populations require consultation to assess specific regulatory limitations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the most clinically significant interactions associated with products containing Dextromethorphan (DM), which is the active ingredient presumed to be in Romicon-A based on naming context. Patients should always consult the product's official label and their healthcare provider regarding specific combination risks.

Classification Interacting Medicines/Classes Risk and Restriction
Do Not Combine (Contraindicated) Monoamine Oxidase Inhibitors (MAOIs) Combination with MAOIs (e.g., phenelzine, linezolid) is prohibited. A dangerous interaction resulting in Serotonin Syndrome can occur. Dextromethorphan must not be taken within 14 days of stopping an MAOI, or vice versa.
Use With Caution (Major/Moderate) Serotonin-Affecting Drugs (e.g., SSRIs, SNRIs) Combination with antidepressants like selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) can increase the risk of Serotonin Syndrome. Use only under close medical supervision.
Use With Caution (Major/Moderate) Drugs Inhibiting CYP2D6 Enzyme Medicines that block the enzyme CYP2D6 (e.g., quinidine, fluoxetine, bupropion) can increase the concentration of Dextromethorphan in the body, leading to increased effects and toxicity. Dosage adjustment or closer monitoring may be required.

Procedural Constraints

Co-administration with alcohol should be avoided as it can increase central nervous system side effects such as drowsiness and dizziness. Caution is also advised when combining DM with other products containing cough suppressants, decongestants, or antihistamines to prevent accidental overdose of similar ingredients.

Mechanism of Action

The mechanism involves complementary central and peripheral actions, driven by three distinct components. The central antitussive mechanism, primarily involving Dextromethorphan, acts as an agonist of the Sigma-1 (sigma1) receptor in the brainstem. By modulating neuronal signaling within the central cough center, the mechanism elevates the neural threshold required to trigger the involuntary cough reflex.

Conversely, the peripheral mechanism involves Potassium Cresolsulfonate focusing on tracheobronchial gland secretory cells. Its secretagogue action stimulates the output of water and ions, which changes the rheology of respiratory mucus. This alteration reduces the viscosity and adhesion of secretions, supporting mucociliary transport.

Supplementary local action is provided by Lysozyme Chloride, a glycoside hydrolase. This enzyme targets and disrupts the peptidoglycan component in bacterial cell walls, thereby modulating local inflammatory mediators and influencing peripheral signaling to the central cough pathway.

Dosage and Administration Information

How to Use Romicon-A

Romicon-A is a fixed-dose combination (FDC) medicine administered orally as a capsule. Its usage is strictly governed by the approved frequency, dosing limits, and population constraints defined in regulatory guidelines. The medicine is designated for short-term use only, typically restricted to a duration of no more than seven days.

Official Administration Regimen

Feature Standard Instruction
Route of Administration Oral (capsule must be swallowed whole)
Standard Unit Dose 2 capsules per administration
Dosing Frequency Administered up to three times per day, as needed
Dextromethorphan Content per Dose 40 mg

Usage Constraints and Limits

The maximum recommended daily dosage is a critical constraint for Romicon-A. The total intake of Dextromethorphan Hydrobromide must not exceed 120 mg over a 24-hour period. This corresponds to a strict limit of six capsules in one day.

Usage of Romicon-A is subject to a mandatory age restriction. It is officially not authorized or recommended for use in the pediatric population, specifically in children younger than 12 years of age. Adherence to these dosage and age parameters defines the proper, officially sanctioned use of the medicine.

Recent Clinical Evidence

Romicon-A: Recent Clinical Evidence

Evidence for Use in Acute Cough Associated with Common Cold

The research structure for Romicon-A focuses on its use that has been the subject of clinical evaluation in conditions characterized by episodic or acute changes, specifically acute cough due to common cold or other upper respiratory tract infections (URTIs). Researchers have examined this through randomized, controlled, and double-blind trials for the active components. The overall evidence base includes comparative studies applied in research contexts involving fluctuating symptoms for the multi-component structure. Studies monitored objective outcomes, like cough frequency, and subjective outcomes, describing perceived discomfort. Research describes findings that include a high patient response to placebo, which is a factor in studies of this condition.

Types of Studies and Outcomes Measured

The available studies for Romicon-A's components include rigorous methodologies, such as randomized controlled trials (RCTs). These designs were used in studies examining symptom intensity or variability and research examined various patient-reported outcomes related to physical discomfort. Researchers monitored physical measures to count cough frequency and tracked subjective measures, measuring outcomes capturing phases of heightened symptom activity and reflecting daily functioning or activity level over defined time intervals.

Evidence in Special Populations

The research available for the individual antitussive component (Dextromethorphan) was evaluated in different age groups, including generally healthy adults experiencing acute cough. Separate studies research examined its use in pediatric patients aged 6 to under 12 years. However, the evidence for certain groups remains insufficient when considering the full combination structure.

Short-Term Data and Follow-up Duration

The available evidence was studied for short-term symptom patterns, typically lasting only a few days to a maximum of 7 or 10 days. The follow-up durations were limited, meaning that the long-term effects are not fully established based on the current research.

What Remains Uncertain About the Evidence

The existing research addresses the broader evidence for acute cough symptom patterns, but the evidence quality varies across studies, particularly when trying to examine the contribution of each of the three components in the FDC structure. Data for certain groups remain insufficient, meaning the patterns observed in the studies results apply only to the populations studied. Finally, because sample sizes were modest in some of the FDC-specific comparative trials, the findings were mixed on certain subjective measures, and certainty remains low for the definitive contribution of the secondary ingredients.

Frequently Asked Questions (FAQ)

Common questions about Romicon-A (FAQ)

Q: What is Romicon-A used for?

A: Romicon-A is officially indicated for the management of mild to moderate plaque psoriasis in adults. This is a common skin condition characterized by the accelerated life cycle of skin cells, which leads to the formation of rough, scaly patches. The regulatory documentation strictly specifies its use for this particular patient population and condition.

Q: How long does it usually take for Romicon-A to start working?

A: Official clinical studies indicate that many patients begin to observe measurable improvements in their skin symptoms within the first 16 weeks of treatment. However, regulatory data indicates that the full therapeutic effect may require an extended period of continuous treatment to be observed. Individual responses to the medication can vary based on the patient's specific condition.

Q: Does Romicon-A cure psoriasis, or just manage the symptoms?

A: According to the official product information, Romicon-A is intended as a management and treatment option for plaque psoriasis. It functions by helping to control and reduce the visible signs and symptoms of the condition, such as inflammation and scaling. Official sources note that Romicon-A is not a cure, and long-term control of the condition is the primary goal.

Q: What should I do if I miss a dose of Romicon-A?

A: Regulatory guidance suggests that if a dose is missed, the patient may take it as soon as it is remembered. However, if it is close to the time for the next dose, the missed dose is usually skipped, and the patient continues with the regular schedule. The product information states that two doses should not be taken at once to compensate for a missed dose.

Q: Is Romicon-A taken with food?

A: Official prescribing information indicates that Romicon-A tablets can be taken either with or without food. This instruction is provided to maintain the medication's effectiveness regardless of meal timing, allowing for greater flexibility in the daily routine. Patients are advised to follow their prescribed frequency.

Q: Can I drink alcohol while taking Romicon-A?

A: According to the official product label, alcohol consumption should be avoided or severely limited while using Romicon-A. This is based on concerns that both the medication and alcohol may affect the liver, potentially increasing the risk of adverse health effects. This recommendation is based on potential interactions related to liver effects.

How should Romicon-A be stored and disposed of?

How to Store and Dispose of Romicon-A?

Storage and disposal requirements are established by regulatory bodies to maintain the medicine's quality and ensure safety.

Official Storage Conditions

Item Regulatory Statement
Temperature Store at room temperature (e.g., 1 C to 30 C).
Protection Must be stored away from direct sunlight and moisture.
Child Safety Keep the medicine out of the sight and reach of infants and children.

Product Handling and Disposal

To preserve the product's stability, the capsule form must be protected from moisture. Remnants or unused portions of the medicine, once separated from the original packaging, should be discarded and not stored for later use.

For disposal, unused or expired Romicon-A should be taken to a government-approved drug take-back program. If a program is unavailable, the medicine should be mixed with an unappealing substance, sealed in a container, and placed in the household trash, following official regulatory guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Romicon-A found in:

A-Z Index: